Logo image of UTI

UNIVERSAL TECHNICAL INSTITUT (UTI) Stock Fundamental Analysis

USA - New York Stock Exchange - NYSE:UTI - US9139151040 - Common Stock

22.91 USD
+1.14 (+5.24%)
Last: 11/25/2025, 8:16:45 PM
23.3261 USD
+0.42 (+1.82%)
Pre-Market: 11/26/2025, 8:00:01 AM
Fundamental Rating

5

We assign a fundamental rating of 5 out of 10 to UTI. UTI was compared to 77 industry peers in the Diversified Consumer Services industry. UTI scores excellent on profitability, but there are some minor concerns on its financial health. UTI has a valuation in line with the averages, but it does not seem to be growing.


Dividend Valuation Growth Profitability Health

7

1. Profitability

1.1 Basic Checks

In the past year UTI was profitable.
UTI had a positive operating cash flow in the past year.
UTI had positive earnings in 4 of the past 5 years.
UTI had a positive operating cash flow in 4 of the past 5 years.
UTI Yearly Net Income VS EBIT VS OCF VS FCFUTI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M -40M 60M 80M

1.2 Ratios

UTI has a Return On Assets of 8.52%. This is in the better half of the industry: UTI outperforms 76.62% of its industry peers.
UTI has a Return On Equity of 20.57%. This is amongst the best in the industry. UTI outperforms 87.01% of its industry peers.
UTI's Return On Invested Capital of 10.86% is amongst the best of the industry. UTI outperforms 83.12% of its industry peers.
The Average Return On Invested Capital over the past 3 years for UTI is below the industry average of 9.62%.
The 3 year average ROIC (5.11%) for UTI is below the current ROIC(10.86%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 8.52%
ROE 20.57%
ROIC 10.86%
ROA(3y)2.68%
ROA(5y)2.09%
ROE(3y)7.52%
ROE(5y)5.81%
ROIC(3y)5.11%
ROIC(5y)N/A
UTI Yearly ROA, ROE, ROICUTI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10 -10 -20 -30

1.3 Margins

With a decent Profit Margin value of 7.79%, UTI is doing good in the industry, outperforming 67.53% of the companies in the same industry.
In the last couple of years the Profit Margin of UTI has grown nicely.
UTI has a better Operating Margin (10.44%) than 67.53% of its industry peers.
In the last couple of years the Operating Margin of UTI has grown nicely.
UTI has a Gross Margin (49.65%) which is in line with its industry peers.
UTI's Gross Margin has declined in the last couple of years.
Industry RankSector Rank
OM 10.44%
PM (TTM) 7.79%
GM 49.65%
OM growth 3Y21.82%
OM growth 5YN/A
PM growth 3Y23.23%
PM growth 5YN/A
GM growth 3Y-14.8%
GM growth 5Y-8.67%
UTI Yearly Profit, Operating, Gross MarginsUTI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 40 60

6

2. Health

2.1 Basic Checks

The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so UTI is still creating some value.
UTI has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
UTI Yearly Shares OutstandingUTI Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
UTI Yearly Total Debt VS Total AssetsUTI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

2.2 Solvency

UTI has an Altman-Z score of 3.35. This indicates that UTI is financially healthy and has little risk of bankruptcy at the moment.
UTI has a Altman-Z score of 3.35. This is in the better half of the industry: UTI outperforms 79.22% of its industry peers.
UTI has a debt to FCF ratio of 0.99. This is a very positive value and a sign of high solvency as it would only need 0.99 years to pay back of all of its debts.
UTI has a Debt to FCF ratio of 0.99. This is amongst the best in the industry. UTI outperforms 84.42% of its industry peers.
UTI has a Debt/Equity ratio of 0.23. This is a healthy value indicating a solid balance between debt and equity.
UTI has a Debt to Equity ratio of 0.23. This is comparable to the rest of the industry: UTI outperforms 54.55% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.23
Debt/FCF 0.99
Altman-Z 3.35
ROIC/WACC1.31
WACC8.32%
UTI Yearly LT Debt VS Equity VS FCFUTI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M 100M 150M 200M 250M

2.3 Liquidity

UTI has a Current Ratio of 1.00. This is a normal value and indicates that UTI is financially healthy and should not expect problems in meeting its short term obligations.
UTI has a Current ratio (1.00) which is in line with its industry peers.
A Quick Ratio of 1.00 indicates that UTI should not have too much problems paying its short term obligations.
UTI has a Quick ratio (1.00) which is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 1
Quick Ratio 1
UTI Yearly Current Assets VS Current LiabilitesUTI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

3

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 54.05% over the past year.
Measured over the past 5 years, UTI shows a small growth in Earnings Per Share. The EPS has been growing by 3.11% on average per year.
EPS 1Y (TTM)54.05%
EPS 3Y3.11%
EPS 5YN/A
EPS Q2Q%0%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%13.28%

3.2 Future

The Earnings Per Share is expected to decrease by -3.86% on average over the next years.
UTI is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 8.52% yearly.
EPS Next Y-18.25%
EPS Next 2Y-3.86%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year8.25%
Revenue Next 2Y8.52%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
UTI Yearly Revenue VS EstimatesUTI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 200M 400M 600M 800M
UTI Yearly EPS VS EstimatesUTI Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 0.5 -0.5 1 -1 -1.5

4

4. Valuation

4.1 Price/Earnings Ratio

With a Price/Earnings ratio of 20.10, UTI is valued on the expensive side.
Compared to the rest of the industry, the Price/Earnings ratio of UTI indicates a somewhat cheap valuation: UTI is cheaper than 62.34% of the companies listed in the same industry.
UTI is valuated rather cheaply when we compare the Price/Earnings ratio to 25.98, which is the current average of the S&P500 Index.
The Price/Forward Earnings ratio is 24.58, which indicates a rather expensive current valuation of UTI.
The rest of the industry has a similar Price/Forward Earnings ratio as UTI.
UTI's Price/Forward Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 35.79.
Industry RankSector Rank
PE 20.1
Fwd PE 24.58
UTI Price Earnings VS Forward Price EarningsUTI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, UTI is valued a bit cheaper than 68.83% of the companies in the same industry.
UTI's Price/Free Cash Flow ratio is a bit cheaper when compared to the industry. UTI is cheaper than 71.43% of the companies in the same industry.
Industry RankSector Rank
P/FCF 16.69
EV/EBITDA 9.46
UTI Per share dataUTI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 5 10

4.3 Compensation for Growth

UTI has a very decent profitability rating, which may justify a higher PE ratio.
A cheap valuation may be justified as UTI's earnings are expected to decrease with -3.86% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-3.86%
EPS Next 3YN/A

0

5. Dividend

5.1 Amount

UTI does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

UNIVERSAL TECHNICAL INSTITUT

NYSE:UTI (11/25/2025, 8:16:45 PM)

Premarket: 23.3261 +0.42 (+1.82%)

22.91

+1.14 (+5.24%)

Chartmill FA Rating
GICS IndustryGroupConsumer Services
GICS IndustryDiversified Consumer Services
Earnings (Last)11-19 2025-11-19/amc
Earnings (Next)02-03 2026-02-03
Inst Owners94.48%
Inst Owner Change-1.21%
Ins Owners2.24%
Ins Owner Change0.24%
Market Cap1.25B
Revenue(TTM)N/A
Net Income(TTM)63.10M
Analysts81.82
Price Target38.18 (66.65%)
Short Float %3.67%
Short Ratio2.95
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly Dividend0.03
Dividend Growth(5Y)-34.43%
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)71.27%
Min EPS beat(2)69.26%
Max EPS beat(2)73.27%
EPS beat(4)4
Avg EPS beat(4)69.47%
Min EPS beat(4)12.21%
Max EPS beat(4)123.12%
EPS beat(8)7
Avg EPS beat(8)80.23%
EPS beat(12)10
Avg EPS beat(12)129.78%
EPS beat(16)14
Avg EPS beat(16)215.22%
Revenue beat(2)2
Avg Revenue beat(2)2.83%
Min Revenue beat(2)1.15%
Max Revenue beat(2)4.51%
Revenue beat(4)4
Avg Revenue beat(4)2.54%
Min Revenue beat(4)1.15%
Max Revenue beat(4)4.51%
Revenue beat(8)8
Avg Revenue beat(8)2.39%
Revenue beat(12)11
Avg Revenue beat(12)2.98%
Revenue beat(16)15
Avg Revenue beat(16)3.43%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-6.02%
EPS NY rev (1m)0%
EPS NY rev (3m)-0.58%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-0.11%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.04%
Valuation
Industry RankSector Rank
PE 20.1
Fwd PE 24.58
P/S 1.54
P/FCF 16.69
P/OCF 11.57
P/B 4.06
P/tB 4.78
EV/EBITDA 9.46
EPS(TTM)1.14
EY4.98%
EPS(NY)0.93
Fwd EY4.07%
FCF(TTM)1.37
FCFY5.99%
OCF(TTM)1.98
OCFY8.64%
SpS14.87
BVpS5.64
TBVpS4.79
PEG (NY)N/A
PEG (5Y)N/A
Graham Number12.02
Profitability
Industry RankSector Rank
ROA 8.52%
ROE 20.57%
ROCE 15.21%
ROIC 10.86%
ROICexc 13.78%
ROICexgc 15.4%
OM 10.44%
PM (TTM) 7.79%
GM 49.65%
FCFM 9.23%
ROA(3y)2.68%
ROA(5y)2.09%
ROE(3y)7.52%
ROE(5y)5.81%
ROIC(3y)5.11%
ROIC(5y)N/A
ROICexc(3y)7.05%
ROICexc(5y)N/A
ROICexgc(3y)7.97%
ROICexgc(5y)N/A
ROCE(3y)7.15%
ROCE(5y)N/A
ROICexgc growth 3Y41.64%
ROICexgc growth 5YN/A
ROICexc growth 3Y37.09%
ROICexc growth 5YN/A
OM growth 3Y21.82%
OM growth 5YN/A
PM growth 3Y23.23%
PM growth 5YN/A
GM growth 3Y-14.8%
GM growth 5Y-8.67%
F-Score6
Asset Turnover1.09
Health
Industry RankSector Rank
Debt/Equity 0.23
Debt/FCF 0.99
Debt/EBITDA 0.58
Cap/Depr 87.82%
Cap/Sales 4.08%
Interest Coverage 11.6
Cash Conversion 88.25%
Profit Quality 118.43%
Current Ratio 1
Quick Ratio 1
Altman-Z 3.35
F-Score6
WACC8.32%
ROIC/WACC1.31
Cap/Depr(3y)259.47%
Cap/Depr(5y)259.17%
Cap/Sales(3y)10.54%
Cap/Sales(5y)10.62%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)54.05%
EPS 3Y3.11%
EPS 5YN/A
EPS Q2Q%0%
EPS Next Y-18.25%
EPS Next 2Y-3.86%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%13.28%
Revenue Next Year8.25%
Revenue Next 2Y8.52%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y85.69%
EBIT growth 3Y58.11%
EBIT growth 5YN/A
EBIT Next Year114.2%
EBIT Next 3Y30.39%
EBIT Next 5YN/A
FCF growth 1Y395.38%
FCF growth 3YN/A
FCF growth 5Y32.12%
OCF growth 1Y222.73%
OCF growth 3Y15.89%
OCF growth 5Y31.61%

UNIVERSAL TECHNICAL INSTITUT / UTI FAQ

What is the fundamental rating for UTI stock?

ChartMill assigns a fundamental rating of 5 / 10 to UTI.


Can you provide the valuation status for UNIVERSAL TECHNICAL INSTITUT?

ChartMill assigns a valuation rating of 4 / 10 to UNIVERSAL TECHNICAL INSTITUT (UTI). This can be considered as Fairly Valued.


Can you provide the profitability details for UNIVERSAL TECHNICAL INSTITUT?

UNIVERSAL TECHNICAL INSTITUT (UTI) has a profitability rating of 7 / 10.


What are the PE and PB ratios of UNIVERSAL TECHNICAL INSTITUT (UTI) stock?

The Price/Earnings (PE) ratio for UNIVERSAL TECHNICAL INSTITUT (UTI) is 20.1 and the Price/Book (PB) ratio is 4.06.


Can you provide the expected EPS growth for UTI stock?

The Earnings per Share (EPS) of UNIVERSAL TECHNICAL INSTITUT (UTI) is expected to decline by -18.25% in the next year.